Early Treatment with Fluvoxamine Among Patients with COVID-19: A Cost-Consequence Model

This paper examined the economic impact of the use of fluvoxamine for early treatment in outpatient populations. A cost-consequence analysis was conducted using a decision-model to assess the health system benefits of the avoidance of progression to severe COVID-19. The analysis found that fluvoxamine is cost-saving for COVID-19 outpatient therapy.

Early Treatment with Fluvoxamine Among Patients with COVID-19: A Cost-Consequence Model,
Platform Life Sciences 2021,
Fergal P. Mills MSc; Gilmar Reis, MD, PhD; Kristian Thorlund PhD; Jamie I. Forrest, PhD, MPH; Christina M. Guo, BCom, David R Boulware, MD, MPH, Professor Edward J. Mills, PhD, FRCP; for the TOGETHER Investigators*

You might be interested


Resilient clinical trial infrastructure in response to the COVID-19 pandemic: Lessons learned from the TOGETHER randomized platform clinical trial

In 2020, clinical trial researchers developed protocols to evaluate the safety and effectiveness of potential treatments for COVID-19. Despite more than 3,000 trials registered , few have generated findings, with the exception of smaller randomized controlled trials.A clinical trial infrastructure (defined as the human, material, and knowledge networks that form a responsive implementation of productive trial protocols) must be resilient to threats (e.g., COVID-19), and is essential when barriers to sustainable funding are common.


Interferon treatments for SARS-CoV-2: Challenges and opportunities

Interferon (IFN) therapies are used to treat a variety of infections and diseases and could be used to treat SARS-CoV-2. However, optimal use and timing of IFN therapy to treat SARS-CoV-2 is not well documented. We aimed to synthesize available evidence to understand whether interferon therapy should be recommended for treatment compared to a placebo or standard of care in adult patients.While IFN therapy has the potential to be a viable treatment for SARS-CoV-2, especially when combined with antivirals and early administration, the lack of comparable of study outcomes prevents evidence synthesis and uptake.



The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is unclear.

Find More Information

Thank you for submitting!